Pharma Focus Asia

AstraZeneca flags return to drug sales growth in 2018

Monday, February 05, 2018

AstraZeneca expects to increase drug sales at a low single-digit percentage rate this year as new medicines win market share and the company puts patent losses behind it, although the need to invest in launches will weigh on profit.

Product sales fell 5 percent in 2017, the company said on Friday.

Fourth-quarter profits were boosted by one-off tax gains with core earnings per share (EPS), which exclude some items, up 7 percent to $1.30 cents on revenue of $5.78 billion.

Analysts, on average, had forecast earnings of 84 cents on revenue of $5.46 billion, Thomson Reuters data showed.

For 2018, AstraZeneca expects core EPS of $3.30 to $3.50.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024